1xbet 한국., Ltd.

1xbet 한국., Ltd. and Esperion Therapeutics, Inc. (headquartered in Michigan, U.S.) announce a licensing agreement in which Otsuka acquires from Esperion exclusive development and commercialization rights in Japan for bempedoic acid (chemical name).

Bempedoic acid, designed by Esperion, has a novel mechanism of action that 1xbet 한국hibits cholesterol and fatty acid synthesis pathways by act1xbet 한국g on ATP (adenos1xbet 한국e triphosphate-citrate lyase, an enzyme that breaks down citric acid 1xbet 한국 the liver).

It is a once-daily, oral therapeutic agent 1xbet 한국 hypercholesterolemia that was developed 1xbet 한국 patients who cannot take statins due to side effects or whose LDL cholesterol levels do not decrease sufficiently when taking statins or other lipid-lowering therapies. Manufacturing and marketing approvals 1xbet 한국 bempedoic acid have been obtained in the U.S. and Europe.

Under the terms of the agreement, 1xbet 한국 will pay Esperion a one-time payment of USD 60 million, as well as milestones in accordance with achievement of development and sales goals. 1xbet 한국 will conduct future clinical trials in Japan and bear the costs. 1xbet 한국 will have exclusive marketing rights in Japan and will pay royalties to Esperion based on sales levels.